Nifurtimox

  • TRADE NAME: Lampit (Bayer)
  • INDICATIONS:

    Approved for treatment of pediatric patients with Chagas disease (American Trypanosomiasis) (caused by Trypanosoma cruzi ).

    Accelerated approval. Continued approval for this indication in pediatric patients may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 


  • CLASS: Antimicrobial, Antiprotozoal
  • HALF-LIFE: 2.4–3.6 hours
  • FDA APPROVAL DATE: 08/06/2020
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    alcohol consumption
  • PREGNANCY: May cause fetal harm when administered to a pregnant woman.

Patients with a history of brain injury, seizures, psychiatric disease, or serious behavioral alterations may experience worsening of their conditions when receiving nifurtimox. Administer nifurtimox under close medical supervision in these patients and in patients who develop neurological disturbances or psychiatric drug reactions.

Nifurtimox has previously been used to treat Chagas disease, mainly in adults, prior to its 2020 FDA approval.

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top